Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 4/20 | 0.38 |
| ▸ | SYK | P43405 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | LYN | P07948 | 2/20 | 0.37 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008155 | 0.84 | CA1 (0.59) | CA1CA2CA12CA9CA3 | |
| SCHEMBL7010232 | 0.83 | CA1 (0.61) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3055994 | 0.82 | CA1 (0.70) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3062109 | 0.82 | CA1 (0.60) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3072116 | 0.81 | CA1 (0.58) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3055161 | 0.81 | CA1 (0.70) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3066997 | 0.81 | CA1 (0.67) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3070387 | 0.81 | CA1 (0.67) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3051454 | 0.79 | CA1 (0.55) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3070425 | 0.79 | CA1 (0.55) | CA1CA2CA12CA9CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0673937-B1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | EISAI CO LTD (JP) | 2003-11-26 | — | — | EP | claimed |
| CN-1079097-C | Heterobicyclic sulfonamide derivatives and sulfonate derivatives | EISAI CO LTD (JP) | 2002-02-13 | — | — | CN | claimed |
| CN-1114506-A | Heterobicyclic sulfonamide derivatives and sulfonate derivatives | EISAI CO LTD (JP) | 1996-01-03 | — | — | CN | claimed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | claimed |
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| CN-100356979-C | Integrin expression inhibitors | EISAI CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1433479-B1 | APPETITE-STIMULATING AGENTS AND REMEDIES FOR ANOREXIA | EISAI R&D MAN CO LTD (JP) | 2007-12-05 | — | — | EP | disclosed |
| US-7015241-B2 | Appetite-stimulating agents and remedies for anorexia | EISAI CO., LTD. (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-20040242628-A1 | Appetite-stimulating agents and remedies for anorexia | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| CN-1551766-A | Lymphocytic activation inhibitor and remedial agent for autoimmune disease | ������������ʽ���� | 2004-12-01 | — | — | CN | disclosed |
| EP-1430894-A1 | LYMPHOCYTIC ACTIVATION INHIBITOR AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE | Eisai Co. Ltd (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-0673937-B1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | EISAI CO LTD (JP) | 2003-11-26 | — | — | EP | disclosed |
| CN-1396833-A | Integrin expression inhibitors | EISAI CO LTD (JP) | 2003-02-12 | — | — | CN | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| CN-1079097-C | Heterobicyclic sulfonamide derivatives and sulfonate derivatives | EISAI CO LTD (JP) | 2002-02-13 | — | — | CN | disclosed |
| CN-1114506-A | Heterobicyclic sulfonamide derivatives and sulfonate derivatives | EISAI CO LTD (JP) | 1996-01-03 | — | — | CN | disclosed |
| EP-0673937-A1 | BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | CA1 867/4885CA2 821/4885CA12 513/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | CA1 867/4885CA2 821/4885CA12 513/4885 |
| US-20040242628-A1 | Appetite-stimulating agents and remedies for anorexia | GHSR, CCKAR, SUCNR1 | CA1 219/4885CA2 208/4885CA12 452/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | CA1 827/4885CA2 631/4885CA12 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.